Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )

torstai 30. heinäkuuta 2026 päivittänyt: Livzon Pharmaceutical Group Inc.

A Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis

This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

244

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Shanghai, Kiina
        • Shanghai Dermatology Hospital

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  1. Aged ≥18 years at screening, male or female.
  2. History of psoriasis for ≥6 months prior to screening, diagnosed as plaque psoriasis according to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 Edition) at screening, and considered by the investigator to be suitable for systemic therapy.
  3. Meeting all three of the following criteria at screening:

    (A)PASI score ≥10;

    (B)sPGA score ≥3;

    (C)BSA ≥10%.

  4. Female participants of childbearing potential must agree to have no pregnancy or egg donation from the time of signing the informed consent form to the end of the study, and voluntarily use highly effective contraceptive measures, except for postmenopausal women; male participants must agree to have no pregnancy (of partner) or sperm donation from the time of signing the informed consent form to the end of the study, and voluntarily use highly effective contraceptive measures. Menopause is defined as meeting one of the following: a) history of bilateral oophorectomy or hysterectomy; b) age ≥55 years, with amenorrhea for ≥12 months without other pathological or physiological reasons; c) age <55 years, with amenorrhea for ≥12 months without other pathological or physiological reasons, and estradiol (E2) <20 pg/mL or follicle-stimulating hormone (FSH) >40 mIU/mL.
  5. Ability to understand and comply with the protocol requirements, and voluntary participation in the clinical trial.

Exclusion Criteria:

  1. History of severe allergic reaction to biological agents, or previous history of severe drug allergy.
  2. Presence of inflammation, ulceration, induration, scar, mass, or other conditions at the injection site that, in the investigator's opinion, preclude subcutaneous injection administration.
  3. Presence of other types of psoriasis at screening, including but not limited to erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, drug-induced psoriasis (including new onset or exacerbation of psoriasis caused by β-blockers, non-steroidal anti-inflammatory drugs, antimalarials, interferons, calcium channel blockers, or lithium).
  4. Presence of severe skin infection, eczema, seborrheic dermatitis, neurodermatitis, or other skin conditions at screening that, in the investigator's assessment, may interfere with the evaluation of psoriasis treatment efficacy.
  5. Meeting any of the following conditions:

    (A)Diagnosed with active tuberculosis infection, including but not limited to active tuberculosis confirmed by imaging;

    (B)Latent tuberculosis infection or close contact with a tuberculosis patient, except in the following cases: a) confirmed by a specialist that standard treatment for latent tuberculosis infection has been completed within 5 years prior to the first dose; b) prophylactic anti-tuberculosis treatment has been initiated at least 4 weeks before the first dose and the subject is willing to continue prophylaxis according to local guidelines; c) the specialist judges that the risk of progression to active tuberculosis is low and that treatment is not required.

    Latent tuberculosis infection is defined as: positive interferon-gamma release assay (IGRA) at screening, without any clinical signs or symptoms of active tuberculosis. Close contact with a tuberculosis patient is defined as: having had close contact (i.e., spending several days or weeks together in a relatively enclosed space) with a patient with active pulmonary tuberculosis within the past 12 months, or having a family member diagnosed with active tuberculosis infection.

  6. History of severe immunodeficiency, including: positive human immunodeficiency virus (HIV) antibody, or other acquired or congenital immunodeficiency diseases.
  7. Presence of any of the following clinically significant conditions:

    (A)History of chronic congestive heart failure with NYHA Class IV; history of echocardiographic cardiac ejection fraction (EF) below 30%;

    (B)Myocardial infarction, acute coronary syndrome, viral myocarditis, or pulmonary embolism within 6 months prior to screening; coronary revascularization within 6 months prior to screening;

    (C)History of severe arrhythmias requiring treatment with Class Ia or Class III antiarrhythmic drugs; history of sick sinus syndrome, second-degree type II or third-degree atrioventricular block without an implanted pacemaker;

    (D)Screening ECG showing QTc interval ≥480 ms (Fridericia correction formula, QTc = QT/(RR^0.33)), or history of prolonged QTc interval and assessed by the investigator as having arrhythmia risk;

    (E)Poorly controlled hypertension within 3 months prior to screening (poorly controlled defined as: blood pressure still not reaching target despite combination therapy with ≥3 antihypertensive agents), or screening systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirmed by repeated measurements;

    (F)History of severe psychiatric disorders such as depression, schizophrenia, schizoaffective disorder, or history of suicidal ideation or suicidal behavior;

    (G)History of severe neurological disorders such as stroke or epilepsy;

    (H)Active bleeding disorders of internal organs, or severe bleeding tendency (e.g., hemophilia);

    (I)Other progressive or uncontrolled systemic diseases that, in the investigator's assessment, may be unstable or may become severe during the trial, making the subject unsuitable for participation.

  8. Meeting either of the following: a) any severe infection within 1 month prior to screening (defined as infection requiring hospitalization or intravenous anti-infective treatment); b) history of opportunistic infections or recurrent, chronic infections that, in the investigator's opinion, could lead to study discontinuation. Opportunistic infections include infections caused by unusual pathogens (e.g., Pneumocystis jirovecii, cryptococcus, etc.) or unusually severe infections caused by common pathogens (e.g., cytomegalovirus, herpes virus, etc.).
  9. History of cancer within 5 years prior to screening, except for cured cutaneous basal cell carcinoma or Stage I squamous cell carcinoma.
  10. History of alcohol abuse (defined as consumption of 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine) or history of illicit drug use within 1 year prior to screening.
  11. Presence of active autoimmune diseases other than psoriasis or psoriatic arthritis (e.g., inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, inflammatory myopathies, mixed connective tissue disease, overlap syndrome, etc.).
  12. Use of topical anti-psoriatic drugs or physical therapy within 2 weeks prior to screening (see prohibited medications/therapies for details).
  13. Use of systemic anti-psoriatic drugs other than biologics within 4 weeks prior to screening (see prohibited medications for details).
  14. Use of TNF-α inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, or IL-17 inhibitors within 3 months or 5 half-lives (whichever is longer) prior to screening (see prohibited medications for details).
  15. Previous participation in and receipt of study drug in the LZM012 clinical trial.
  16. Participation in any clinical trial of an investigational drug (defined as having received study drug) within 3 months or 5 half-lives of the investigational drug (whichever is longer) prior to screening.
  17. Any of the following laboratory results at screening:

    (A)Hematology: hemoglobin (HGB) <90 g/L; platelet count (PLT) <100 × 10⁹/L; white blood cell count (WBC) <3 × 10⁹/L; absolute neutrophil count (NEUT) <1.5 × 10⁹/L;

    (B)Liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN), or total bilirubin >1.5 times ULN;

    (C)Renal function: serum creatinine >1.5 times ULN.

  18. Receipt of a live vaccine (including attenuated live vaccine) within 3 months prior to screening, or planned receipt of a live vaccine (including attenuated live vaccine) during the trial.
  19. Meeting any of the following at screening:

    (A)Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with further testing showing HBV-DNA ≥500 IU/mL;

    (B)Positive hepatitis C virus (HCV) antibody with further testing showing HCV RNA positive;

    (C)Positive syphilis specific antibody with further testing showing positive syphilis non-specific antibody (including but not limited to rapid plasma reagin (RPR) test, toluidine red unheated serum test (TRUST), etc.).

  20. Pregnant or breastfeeding women, or positive pregnancy test result at screening.
  21. Any other condition or situation that, in the investigator's opinion, makes the subject unsuitable for participation in this trial.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: LZM012 Monotherapy Group
320mg LZM012 subcutaneous injection every 4 weeks for 3 doses, no dose adjustment permitted.
Rekombinantti anti-ihminen IL-17A/F humanisoitu monoklonaalinen vasta-aineinjektio

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
PASI100 vastausprosentti
Aikaikkuna: Viikolla 12
Potilassuhde saavutti PASI100:n (PASI100 vasteprosentti)
Viikolla 12

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Time to first achievement of PASI50, PASI75, PASI90 and PASI100
Aikaikkuna: Up to Week 12
Up to Week 12
PASI75/PASI90 response rate
Aikaikkuna: At week 4、 At week 8、 At week 12
At week 4、 At week 8、 At week 12
Absolute and relative percentage change from baseline in PASI score at each visit
Aikaikkuna: at Week 4, Week 8, Week 12
at Week 4, Week 8, Week 12
sPGA 0/1 response rate
Aikaikkuna: At week 4、 At week 8、 At week 12
At week 4、 At week 8、 At week 12
change in Dermatology Life Quality Index (DLQI) score
Aikaikkuna: At week 4、 At week 8、 At week 12
Dermatology Life Quality Index (DLQI) Score range: 0 to 30; higher scores indicate worse health-related quality of life.
At week 4、 At week 8、 At week 12
treatment-emergent adverse events
Aikaikkuna: up to week 16
up to week 16
Vital signs: systolic blood pressure
Aikaikkuna: Up to Week 16
Up to Week 16
Vital signs: diastolic blood pressure
Aikaikkuna: Up to Week 16
Up to Week 16
Vital signs: pulse rate
Aikaikkuna: up to week 16
up to week 16
Vital signs: tympanic temperature
Aikaikkuna: up to week 16
up to week 16
Electrocardiogram (ECG): PR interval, QT interval
Aikaikkuna: Up to Week 16
Up to Week 16
Electrocardiogram (ECG): heart rate
Aikaikkuna: up to week 16
up to week 16
physical examinatio: Proportion of subjects with abnormal skin findings on physical examination
Aikaikkuna: Up to Week 16
Up to Week 16
physical examination:Proportion of subjects with abnormal head and neck findings on physical examination
Aikaikkuna: up to week 16
up to week 16
physical examination:Proportion of subjects with abnormal chest findings on physical examination
Aikaikkuna: up to week 16
up to week 16
physical examination:Proportion of subjects with abnormal abdomen findings on physical examination
Aikaikkuna: up to week 16
up to week 16
physical examination:Proportion of subjects with abnormal extremities findings on physical examination
Aikaikkuna: up to week 16
up to week 16
Incidence of anti-drug antibody (ADA) and neutralizing antibody (NAb) positive
Aikaikkuna: From baseline to Week 12
From baseline to Week 12
Laboratory tests: hematology:Platelet count, Neutrophil count, Lymphocyte count, White blood cell (WBC) count
Aikaikkuna: up to week 16
up to week 16
Laboratory tests: hematology:Hemoglobin (Hb)
Aikaikkuna: up to week 16
up to week 16
Laboratory tests: hematology:Hematocrit (Hct), Neutrophil percentage
Aikaikkuna: up to week 16
up to week 16
Laboratory tests: serum biochemistry:Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Creatine phosphokinase (CPK)
Aikaikkuna: up to week 16
up to week 16
Laboratory tests: serum biochemistry:Total bilirubin (TBIL), Direct bilirubin (DBIL), Creatinine (Cr), Uric acid (UA);
Aikaikkuna: up to week 16
up to week 16
Laboratory tests: serum biochemistry:Total cholesterol (TC), Triglycerides (TG), Low-density lipoprotein cholesterol (LDL-C), Glucose (GLU)
Aikaikkuna: up to week 16
up to week 16
Laboratory tests: urinalysis:Urine protein, urine glucose, urine ketone bodies;
Aikaikkuna: up to week 16
up to week 16
Laboratory tests: urinalysis:Urine leukocytes, urine erythrocytes
Aikaikkuna: up to week 16
up to week 16

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 23. kesäkuuta 2025

Ensisijainen valmistuminen (Todellinen)

Maanantai 26. tammikuuta 2026

Opintojen valmistuminen (Todellinen)

Maanantai 26. tammikuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 8. heinäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 30. heinäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 5. elokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 5. elokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 30. heinäkuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. heinäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • LZM012-302

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .